In HER2+ BC, the integration of HER2-targeted treatments (e.g., trastuzumab) with ICIs has been evaluated, with evidence indicating that the combination may improve outcomes in patients with PDL1+ tumors. This evidence concerns the gene CD274 and breast cancer.